Non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinical development. This article in SelectScience® explores the evolving NIT landscape, emerging regulat...
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Flexible formulation strategies boost early phase clinical success
Early phase clinical success relies on simple, flexible formulations that can adapt to wide dose ranges, support matching placebos, and deliver reliable stability. This article explores how formulation strategies enable dose escalation, maintain blinding integrity, and streamline development in first‑in‑human trials. It also highlights practical considerations for selecting dosage forms and designing stability programs that balance speed, cost, and clinical needs.
-
2025 in Review: Global biotech and funding trends
In this interview, Deepali Suri, President of ICON Biotech, breaks down the key trends shaping today’s biotech industry and their global impact. Using insights from ICON’s global and China biotech surveys, capturing input from more than 260 biotech leaders worldwide, Suri highlights emerging therapeutic innovations, the growing influence of AI in R&D, and how geopolitical tensions are redefining international drug development strategies.
-
More than a statistic: What EU Joint Clinical Assessment changes for oncology patients
This article by Dr. Liz O’Brien of ICON, outlines how the EU Joint Clinical Assessment is reshaping global oncology drug development by driving earlier evidence generation, strengthening patient‑centered trial design and enabling more equitable access to innovative treatments across Europe. It underscores the growing emphasis on patient insights, PROs and cross‑functional evidence planning one year after JCA implementation.
-
The “R” in CRO: How and why CROs should harness open-source R software
In this Journal of mHealth article, Ashish Koul explains how open-source R software empowers CROs to modernise statistical workflows, cut costs and deliver more transparent, scalable analyses.
-
From biopsy bottlenecks to biomarker breakthroughs - how non-invasive tools are reshaping MASH trials
This article examines how non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinical development. It also outlines the rapidly evolving NIT landscape, emerging regulatory perspectives, and key opportunities to optimise MASH trial design and execution.
-
How digital health technologies are reshaping clinical development
Digital health technologies are rapidly becoming essential to clinical trial strategies as regulators and sponsors embrace them to streamline operations, reduce patient burden, and generate higher‑quality real‑world data.
-
Submitting clinical data to the FDA and PDMA: An efficient and compliant approach
In this article, our data standards experts explain how sponsors can efficiently prepare clinical data submissions that meet both FDA and PMDA requirements by leveraging the substantial alignment between the two agencies’ standards.
-
The formula for biotech success in 2026: Confidence, resilience and funding
For biotech companies the past two years have been challenging. In 2025 ICON Biotech conducted a follow-up survey of biotech leaders, previously carried out in 2023. The new results show changing trends in the risks, challenges and opportunities in the biotech sector.
-
The solution to persistent startup bottlenecks? Refocusing on site centricity
Study startup, and specifically, feasibility, site selection and activation, remains one of the most critical yet challenging early phases of clinical trial delivery. The solution to persistent startup bottlenecks? Refocusing on site centricity.
-
Interview series: Part 1 of 5 - Rethinking site activation to cut startup timelines
How contract standardisation, proactive budget alignment, and AI-enabled negotiation tools can reduce site activation delays and turn agreements into strategic accelerators.
